

# Prenatal Exposure to Acetaminophen and Risk of ADHD

Eivind Ystrom, PhD,<sup>a,b,c</sup> Kristin Gustavson, PhD,<sup>a,b</sup> Ragnhild Eek Brandlistuen, PhD,<sup>a</sup> Gun Peggy Knudsen, PhD,<sup>a</sup> Per Magnus, MD,<sup>a,d</sup> Ezra Susser, MD,<sup>e,f</sup> George Davey Smith, MD,<sup>g</sup> Camilla Stoltenberg, MD,<sup>a,h</sup> Pål Surén, MD,<sup>a</sup> Siri E. Håberg, MD,<sup>a</sup> Mady Hornig, MD,<sup>e</sup> W. Ian Lipkin, MD,<sup>e</sup> Hedvig Nordeng, PhD,<sup>a,c</sup> Ted Reichborn-Kjennerud, MD<sup>a,d</sup>

abstract

**OBJECTIVES:** To estimate the association between maternal use of acetaminophen during pregnancy and of paternal use before pregnancy with attention-deficit/hyperactivity disorder (ADHD) in offspring while adjusting for familial risk for ADHD and indications of acetaminophen use.

**METHODS:** Diagnoses were obtained from the Norwegian Patient Registry for 112 973 offspring from the Norwegian Mother and Child Cohort Study, including 2246 with ADHD. We estimated hazard ratios (HRs) for an ADHD diagnosis by using Cox proportional hazard models.

**RESULTS:** After adjusting for maternal use of acetaminophen before pregnancy, familial risk for ADHD, and indications of acetaminophen use, we observed a modest association between any prenatal maternal use of acetaminophen in 1 (HR = 1.07; 95% confidence interval [CI] 0.96–1.19), 2 (HR = 1.22; 95% CI 1.07–1.38), and 3 trimesters (HR = 1.27; 95% CI 0.99–1.63). The HR for more than 29 days of maternal acetaminophen use was 2.20 (95% CI 1.50–3.24). Use for <8 days was negatively associated with ADHD (HR = 0.90; 95% CI 0.81–1.00). Acetaminophen use for fever and infections for 22 to 28 days was associated with ADHD (HR = 6.15; 95% CI 1.71–22.05). Paternal and maternal use of acetaminophen were similarly associated with ADHD.

**CONCLUSIONS:** Short-term maternal use of acetaminophen during pregnancy was negatively associated with ADHD in offspring. Long-term maternal use of acetaminophen during pregnancy was substantially associated with ADHD even after adjusting for indications of use, familial risk of ADHD, and other potential confounders.



<sup>a</sup>Norwegian Institute of Public Health, Oslo, Norway; <sup>b</sup>Section of Health, Developmental, and Personality Psychology, Department of Psychology, <sup>c</sup>PharmacoEpidemiology and Drug Safety Research Group, School of Pharmacy, and <sup>d</sup>Faculty of Medicine, University of Oslo, Oslo, Norway; <sup>e</sup>Mailman School of Public Health, Columbia University, New York, New York; <sup>f</sup>New York State Psychiatric Institute, New York, New York; <sup>g</sup>Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom; and <sup>h</sup>Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Dr Ystrom designed the study, conducted analyses, and drafted the initial manuscript; Drs Gustavson, Brandlistuen, Susser, Davey Smith, Stoltenberg, Surén, Håberg, Hornig, Lipkin, Nordeng, and Reichborn-Kjennerud contributed substantially to the conception and design of the study and critically reviewed the manuscript for important intellectual content; Dr Knudsen contributed substantially in the acquisition of data by coordinating the registry linkage and critically reviewed the manuscript for important intellectual content; Dr Magnus contributed substantially in the acquisition of data by leading the data collection of the Norwegian Mother and Child Cohort study and critically reviewed the manuscript for important intellectual content; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**DOI:** <https://doi.org/10.1542/peds.2016-3840>

**WHAT'S KNOWN ON THIS SUBJECT:** In previous studies, researchers have identified an association between acetaminophen use during pregnancy and attention-deficit/hyperactivity disorder (ADHD) in offspring. Maternal use of acetaminophen is associated with impulsivity; hence, it is unknown if the association is due to indications of use or familial risk for ADHD.

**WHAT THIS STUDY ADDS:** After adjusting for familial risk for ADHD, indications of use, and acetaminophen use before pregnancy, long-term acetaminophen use during pregnancy is related to more than a twofold increase in risk for offspring ADHD.

**To cite:** Ystrom E, Gustavson K, Brandlistuen RE, et al. Prenatal Exposure to Acetaminophen and Risk of ADHD. *Pediatrics*. 2017;140(5):e20163840

Acetaminophen is the recommended medication for pregnant women with fever or pain and is widely used during pregnancy. Reports have suggested that acetaminophen is used by ~65% to 70% of pregnant women in the United States and by ~50% to 60% of pregnant women in western and northern Europe.<sup>1,2</sup> Acetaminophen crosses the placenta and can be traced in the infant's urine after prenatal exposure.<sup>3</sup> In 2013, researchers conducting a sibling comparison in a large, population-based Norwegian birth cohort study suggested that prenatal acetaminophen use for 28 or more days was associated with poorer motor and communicational development and externalizing problems (ie, inattentiveness and aggression) in offspring.<sup>4</sup> The following year, researchers conducting a large Danish birth cohort study found an association between prenatal acetaminophen use and both a clinical attention-deficit/hyperactivity disorder (ADHD) diagnosis and ADHD symptoms in offspring<sup>5</sup>; later, researchers in other studies related prenatal acetaminophen use to rating scales of disinhibited behavior.<sup>6,7</sup>

The Danish study<sup>5</sup> had several strengths, including prospective assessment, a large sample size, and a number of relevant covariates. It also had some important limitations, especially possible residual confounding.<sup>8</sup> Acetaminophen is recommended for pregnant women with fever and pain; it is also used for a wide array of other inflammatory conditions during pregnancy. Furthermore, it has been suggested that the presence of some of these conditions during pregnancy (eg, fever, inflammation, and autoimmunity) are associated with increased risk of neurodevelopmental disorders in offspring.<sup>9–12</sup> To investigate potential adverse effects of acetaminophen on fetal development, it is therefore

essential to allow for the potential influence of such underlying conditions. We have previously found that an impulsive personality is associated with acetaminophen use during pregnancy.<sup>13</sup> It is therefore possible that acetaminophen use during pregnancy could be influenced by familial factors (including genetic influences) that may also influence the risk of offspring ADHD. It is therefore important to adjust for parental symptoms of ADHD.

If the association between acetaminophen use during pregnancy and offspring ADHD is due to unobserved maternal factors (eg, impulsive personality traits<sup>13</sup>), we would expect use before pregnancy to be no less associated with offspring ADHD than use during pregnancy. Prepregnancy use therefore serves as a negative control for the specificity of the gestational effect.<sup>14</sup>

If the association is due to unobserved familial factors (eg, genetic factors), paternal use of acetaminophen may also be associated with ADHD in a way similar to maternal use of acetaminophen. However, acetaminophen and endocrine disruptors have been shown to have potential for transgenerational disease transmission effects in mouse models via male germ-line epigenetic effects, and endocrine disruption effects of acetaminophen have been shown in the human testis.<sup>15,16</sup> It is therefore important to estimate the effect of paternal prepregnancy use.

In the current study, we used data from a large, prospective, population-based birth cohort from Norway to examine whether acetaminophen use during pregnancy was associated with ADHD in the offspring after adjusting for potential confounders. In contrast to researchers in previous studies, we were able to adjust for indications of acetaminophen use and parental symptoms of ADHD. We were furthermore able to analyze

maternal use of acetaminophen before pregnancy as a negative control<sup>17</sup> and to estimate the effect of paternal use before pregnancy on offspring ADHD.

## METHODS

### Sample

Data were drawn from the Norwegian Mother and Child Cohort Study (MoBa) conducted by the Norwegian Institute of Public Health.<sup>18</sup> Invitations were sent by mail to pregnant women in Norway in connection with the routine ultrasound examination offered at the local hospitals around pregnancy week 18, and 40.6% of the invited women consented to participate. The cohort includes 114 744 children born between 1999 and 2009, 95 242 mothers, and 75 217 fathers from all over Norway. The establishment and data collection in MoBa has obtained a license from the Norwegian Data Inspectorate and approval from the Regional Committee for Medical Research Ethics. The current study was approved by the Regional Committee for Medical Research Ethics. Self-report questionnaires were sent to the mothers and fathers at approximately 18 weeks of gestation and to mothers later in pregnancy and after delivery. We used information from maternal questionnaires when children were 6 months old, 1.5 years old, and 3 years old in version 9 of the quality-assured MoBa data files. We excluded 1283 study subjects who died or emigrated during childhood and 488 subjects without a recorded date of birth in the Medical Birth Registry of Norway. Our final sample comprised the eligible 112 973 children and their parents.

### Measure of ADHD

We obtained information about children's ADHD diagnosis from the Norwegian Patient Registry (NPR).<sup>19</sup> Since 2008, all government-owned

and government-financed hospitals and outpatient clinics mandatorily report individual-level *International Classification of Diseases, 10th Revision* diagnoses<sup>20</sup> to NPR to receive financial reimbursement. By using individual personal identification numbers, diagnostic information from NPR was linked to MoBa. Thus, all MoBa children registered with an *International Classification of Diseases, 10th Revision* diagnosis of hyperkinetic disorder (F90.0, F90.1, F90.8, or F90.9) between 2008 and 2014 were identified and regarded as having ADHD. Hyperkinetic disorder requires the combination of inattentive and hyperactive symptoms, and as a result, hyperkinetic disorder is a subtype nested within the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* classification of ADHD.<sup>21</sup> In comparison with ADHD, hyperkinetic disorder is characterized by a higher proportion of patients with impaired language and motor development.<sup>22</sup> Two cases were excluded from the analyses because of an F90 diagnosis before the age of 3.

### Prenatal Use of Acetaminophen

Information on acetaminophen use was obtained through MoBa questionnaires. Acetaminophen use was available from 2 prenatal and 1 postnatal questionnaires. At week 18, week 30, and 6 months postpartum, the mothers were asked to report on 77, 32, and 19 different medical conditions, respectively. The mothers reported details on medication use specifically for each medical condition. In addition, at each time point, the mothers listed names of any additional medications used. For each indication, the mother could name the medication taken in an open textbox and specify the following exposure windows: 6 months before gestation; gestational weeks 0 to 4, 5 to 8, 9 to 12, and

$\geq 13$  (until completion of the first questionnaire); 13 to 16, 17 to 20, 21 to 24, 25 to 28, and  $\geq 29$  (until completion of the second questionnaire); and  $\geq 30$  (until birth), 0 to 3 months postpartum, and 4 to 6 months postpartum. Use 6 months before gestation was reported on 53 of the 77 indications reported at week 18. In addition, mothers were asked to report all other medication use for all exposure windows in all questionnaires. Questionnaires can be found at [www.fhi.no](http://www.fhi.no).

Number of days was reported as a total across all exposure windows in each questionnaire. The percentage of indications relating to acetaminophen use having 0, 1, or  $\geq 2$  comedications were 88.9%, 10.0%, and 1.1%, respectively. Fathers filled out a separate questionnaire at gestational week 18. Therein, they reported their medication use for the last 6 months before pregnancy. We classified and grouped medication exposure according to the Anatomic Therapeutic Chemical Classification System developed by the World Health Organization.<sup>23</sup> Acetaminophen exposure was defined as using a drug with the Anatomic Therapeutic Chemical code N02BE01.

### Covariates

On the basis of previous literature, the following covariates were considered potential confounders: parental symptoms of ADHD (in MoBa, these are measured by the 6-item World Health Organization adult ADHD self-report scale screener<sup>24</sup> measuring risk for the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* classification of ADHD), maternal self-reported alcohol use during pregnancy, maternal self-reported daily smoking during pregnancy, symptoms of anxiety and depression at the 18th and 30th week of gestation (in MoBa, this is measured by the 5- and 8-item short version

of the Hopkins Symptom Checklist 25),<sup>25,26</sup> maternal education, marital status, BMI at the 18th week of gestation, maternal age, parity, birth year centered to 1999, and birth year squared to adjust for nonlinear cohort effects. Maternal age and parity were obtained from the Medical Birth Registry of Norway.<sup>27</sup> In addition, we assessed 128 medical conditions at the 17th week and 30th week of gestation and at 6 months postpartum. Acetaminophen was used for 96 of these indications.

### Statistical Analyses

The associations between acetaminophen use and offspring ADHD were examined in Cox proportional hazard models with the offspring's age in months as the time metric. Offspring were defined as being at risk from 3 years of age and were followed to the time of ADHD diagnosis or censored at December 31, 2014. To replace missing values on self-reported covariates, we used multiple imputation with 50 imputations<sup>28</sup>.


For the analysis in which we investigated duration of acetaminophen use, we used the indication nested within each mother as our observational unit. For example, a mother having used acetaminophen for 5 out of the 128 possible indications at any time point during pregnancy contributed 5 units in the analyses (ie, 1 for each indication of use). Because the number of days was reported as a total across all exposure windows in each questionnaire, we adjusted the analyses of number of days used for number of comedications, use before pregnancy, and use after pregnancy within each indication. We grouped the effects of use across types of indications (ie, fever and infections, pain conditions, and indication not specified). We used a stratified Cox model to account for duration of acetaminophen use, with indications as strata. To account for clustering

of indications within mothers, we used robust standard errors. We used Stata version 14.1 (StataCorp, College Station, TX) for all analyses.<sup>29</sup>

## RESULTS

The study population included 112 973 children, of whom 2246 had been diagnosed with ADHD. In Fig 1, we present the estimated cumulative number of expected ADHD events across age. We estimated that ~4% of children in MoBa will have an ADHD diagnosis at the age of 13 (Fig 1). Fifty-two thousand seven-hundred and seven (46.7%) women used acetaminophen during pregnancy (Table 1). Twenty-seven percent used acetaminophen in 1 trimester, 16% in 2 trimesters, and 3.3% in all 3 trimesters. Maternal preconceptional use and use in the first trimester was approximately equally associated ( $r = 0.49$ ) with use in the first and second trimester ( $r = 0.56$ ) and use in the second and third trimester ( $r = 0.49$ ) (Supplemental Table 4). Paternal use was associated with maternal preconceptional use and use during pregnancy ( $r = 0.18$ – $0.10$ ) (Supplemental Table 4).

Offspring prenatally exposed to acetaminophen had an increased unadjusted hazard rate of ADHD of 17%, 39%, and 46% after 1, 2, and 3 trimesters of exposure, respectively (Table 1). These associations were not attenuated when we adjusted for maternal and paternal use before pregnancy (model 1), but they were slightly lower after we adjusted for parental symptoms of ADHD (model 2). In model 3, we adjusted for a range of potential confounders (Supplemental Table 5), and the hazard ratios (HRs) for the associations between 1, 2, and 3 trimesters of prenatal acetaminophen exposure were 1.07 (95% confidence interval [CI] 0.96–1.19), 1.22 (95% CI 1.07–1.38), and 1.27 (95% CI 0.99–1.63), respectively. The negative control, maternal preconceptional



**FIGURE 1**

The figure depicts the Nelson-Aalen cumulative hazard estimate and the estimated proportion of children receiving an ADHD diagnosis by age after birth.

use of acetaminophen, had no effect on offspring ADHD. Paternal preconceptional use had no weaker effect than maternal use during pregnancy (Table 1).

In Table 2, we present the HRs for offspring ADHD by number of days of prenatal acetaminophen exposure, adjusted for each indication of use by stratification. We found that use of acetaminophen <7 days was negatively associated with offspring ADHD. For use >7 days, the HR for offspring ADHD increased with the number of days exposed. Prenatal use of acetaminophen for 29 or more days was associated with a substantially increased hazard rate of ADHD (HR = 2.20; 95% CI 1.50–3.24), even after adjusting for indications of use by stratification (Supplemental Table 6). The associations with use of 29 days or more did not differ across groups of indications (HR = 2.13–2.56). Acetaminophen use for fever and infections for 22 to 28 days was strongly associated with ADHD (HR = 6.15; 95% CI 1.71–22.05). Associations between paternal preconceptional use of acetaminophen and ADHD are presented in Table 3. Short-term paternal use was not negatively

associated with ADHD (HR = 1.10; 95% CI 0.92–1.30); paternal use for 29 days or more was as strongly associated with ADHD (HR = 2.06; 95% CI 1.36–3.13) as the corresponding maternal prenatal use.

## DISCUSSION

We found maternal prenatal acetaminophen use to be associated with a higher hazard rate for offspring ADHD, supporting the findings of Liew et al<sup>13</sup> based on Danish registry data. Liew et al<sup>13</sup> did not, however, control for the indications for use or ADHD-related familial factors. In our study, the association persisted after adjusting for acetaminophen use before pregnancy and for parental symptoms of ADHD. We had the advantage of having medication data separately for each indication, allowing us to account for confounding by each indication in a stratified model. Offspring prenatally exposed to acetaminophen for 29 days or more had a twofold HR for receiving a clinical diagnosis of ADHD from specialist health services. This estimate was the same regardless of indication (ie, fever and infections

**TABLE 1** HRs for ADHD Diagnosis According to Maternal Acetaminophen Use During Pregnancy in 112973 Offspring

	Complete Cases			Estimated Data by Multiple Imputation			HRs		
	n	Total n	%	n	%	Crude	Model 1	Model 2	Model 3
							Adjusted (95% CI)	Adjusted (95% CI)	Adjusted (95% CI)
Acetaminophen use 6 mo before pregnancy	27 584	104 084	26.5	29 931	26.5	1.04	0.93 (0.83–1.03)	0.92 (0.82–1.02)	0.95 (0.85–1.06)
Paternal acetaminophen use	11 119	61 543	18.1	20 151	17.8	1.34	1.31 (1.12–1.53)	1.26 (1.08–1.48)	1.27 (1.08–1.49)
Acetaminophen use during pregnancy									
Never used during pregnancy	45 615	93 216	48.9	60 266	53.3	1.00	1.00 (reference)	1.00 (reference)	1.00 (reference)
Ever used during pregnancy	47 601	93 216	51.1	52 707	46.7	1.26	1.25 (1.14–1.37)	1.20 (1.09–1.32)	1.12 (1.02–1.24)
Any 1 trimester	23 244	85 854	27.1	30 610	27.1	1.17	1.17 (1.05–1.30)	1.13 (1.01–1.27)	1.07 (0.96–1.19)
First trimester only	7 448	85 854	8.7	9 282	8.2	1.15	1.15 (0.97–1.36)	1.14 (0.97–1.36)	1.12 (0.94–1.32)
Second trimester only	14 688	85 854	17.1	19 927	17.6	1.17	1.17 (1.03–1.33)	1.13 (0.99–1.28)	1.04 (0.92–1.18)
Third trimester only	1 108	85 854	1.3	1 401	1.2	1.21	1.21 (0.80–1.83)	1.12 (0.74–1.69)	1.12 (0.75–1.67)
Any 2 trimesters	13 698	85 854	16.0	18 379	16.3	1.39	1.39 (1.23–1.60)	1.32 (1.16–1.50)	1.22 (1.07–1.38)
Both first and second trimesters	11 536	85 854	13.4	15 254	13.5	1.37	1.38 (1.20–1.60)	1.32 (1.15–1.51)	1.21 (1.06–1.39)
Both second and third trimesters	1 653	85 854	1.9	2 389	2.1	1.46	1.46 (1.06–2.00)	1.30 (0.95–1.78)	1.20 (0.87–1.66)
Both first and third trimesters	509	85 854	0.6	737	0.7	1.44	1.45 (0.83–2.52)	1.35 (0.77–2.34)	1.34 (0.77–2.34)
All 3 trimesters	2 908	85 854	3.4	3 718	3.3	1.46	1.46 (1.15–1.71)	1.34 (1.05–1.71)	1.27 (0.99–1.63)

Two thousand two hundred and forty six children were diagnosed with ADHD by December 31, 2014. All estimates are adjusted for birth year, model 2 is furthermore adjusted for parental ADHD symptoms, and model 3 is furthermore adjusted for alcohol use during pregnancy, smoking during pregnancy, symptoms of anxiety and depression during pregnancy, maternal education, marital status, BMI at 17th week of gestation, maternal age, and parity.

or pain conditions). Maternal use of acetaminophen for <8 days was negatively associated with ADHD. The association between paternal preconceptional acetaminophen use and ADHD was similar to the association between maternal use of acetaminophen during pregnancy and ADHD.

The considerable increased rate of ADHD associated with long-term prenatal exposure to acetaminophen (ie, >29 days) is in line with the findings of Brandlistuen et al,<sup>4</sup> who also found small associations for short-term use and large associations for long-term use among discordant siblings in a subset of MoBa. Liew et al<sup>13</sup> also found stronger associations by increasing number of weeks exposed.

ADHD is highly familial in both children and adults.<sup>30</sup> We have previously found that acetaminophen use during pregnancy was associated with impulsive personality traits in mothers.<sup>13</sup> Therefore, our ability to adjust for parental symptoms of ADHD represents a considerable improvement compared to previous study designs. With our analyses, we showed that the association between maternal acetaminophen use and ADHD did not appear to be strongly confounded by common familial (eg, genetic) factors for ADHD and use of acetaminophen. Researchers in previous studies have also suggested common familial risk factors for maternal depression and offspring disruptive behavior.<sup>31,32</sup> We examined this by adjusting for maternal symptoms of depression, but the association remained.

Even after adjusting for indications of use, there was still an association (HR = 2.20; 95% CI 1.50–3.24) between long-term prenatal acetaminophen exposure and childhood ADHD. This estimate was similar across several indications for acetaminophen use (fever, infections, and pain conditions). This indicates that putative confounding factors for long-term acetaminophen use and

**TABLE 2** HRs for Offspring ADHD by Number of Days of Maternal Acetaminophen Use During Pregnancy

	All Indications				Fever and Infections				Groups of Indications for Acetaminophen Use				Indication Not Specified	
	Adjusted HR <sup>a</sup> (95% CI)		No. of Mothers Reporting Each Exposure Duration / Overall No. of Observations of Use per Exposure Duration		Adjusted HR <sup>a</sup> (95% CI)		No. of Mothers Reporting Each Exposure Duration / Overall No. of Observations of Use per Exposure Duration		Adjusted HR <sup>a</sup> (95% CI)		No. of Mothers Reporting Each Exposure Duration / Overall No. of Observations of Use per Exposure Duration		Adjusted HR <sup>a</sup> (95% CI)	
	No. of Mothers Reporting Each Exposure Duration	Adjusted HR <sup>a</sup> (95% CI)	No. of Mothers Reporting Each Exposure Duration	Overall No. of Observations of Use per Exposure Duration	No. of Mothers Reporting Each Exposure Duration	Adjusted HR <sup>a</sup> (95% CI)	No. of Mothers Reporting Each Exposure Duration	Overall No. of Observations of Use per Exposure Duration	No. of Mothers Reporting Each Exposure Duration	Adjusted HR <sup>a</sup> (95% CI)	No. of Mothers Reporting Each Exposure Duration	Overall No. of Observations of Use per Exposure Duration	No. of Mothers Reporting Each Exposure Duration	Adjusted HR <sup>a</sup> (95% CI)
No use	103017	1.00 Reference	84304	1.00 Reference	75019	1.00 Reference	4606	1.00 Reference	4606	1.00 Reference	4606	1.00 Reference	4606	1.00 Reference
1–7 d	1153338	0.90 (0.81–1.00)	216206	0.90 (0.75–1.09)	180288	0.89 (0.76–1.04)	4639	0.89 (0.76–1.04)	4639	1.30 (0.98–1.75)	19154	1.30 (0.98–1.75)	19154	1.30 (0.98–1.75)
8–14 d	36889	1.18 (0.98–1.42)	8752	1.02 (0.55–1.89)	10335	1.12 (0.83–1.50)	21796	1.12 (0.83–1.50)	21796	1.96 (1.36–2.82)	21796	1.96 (1.36–2.82)	21796	1.96 (1.36–2.82)
15–21 d	53667	1.35 (1.00–1.81)	1021	0.98 (0.24–3.95)	2653	1.43 (0.96–2.14)	1949	1.43 (0.96–2.14)	1949	1.79 (0.95–3.35)	2020	1.79 (0.95–3.35)	2020	1.79 (0.95–3.35)
22–28 d	7923	1.60 (0.70–3.69)	185	6.15 (1.71–22.05)	1045	2.56 (1.54–4.25)	441	2.56 (1.54–4.25)	441	—	447	—	447	—
29 or more d	2003	2.20 (1.50–3.24)	200	2.40 (0.34–16.78)	1147	—	61	—	61	—	61	—	61	—
	253	—	16	—	133	—	62	—	62	—	62	—	62	—
	283	—	17	—	138	—	200	—	200	—	200	—	200	—
	1034	—	72	—	609	—	212	—	212	—	212	—	212	—
	1395	—	75	—	772	—	—	—	—	—	—	—	—	—

—, not applicable.

<sup>a</sup> Adjusted for year of birth, maternal age, parity, comedication within each indication of use, acetaminophen use first 6 months before pregnancy within each indication of use (only reports on first trimester are adjusted), and acetaminophen use in the first 6 months postpartum within each indication of use (only reports on last trimester are adjusted). Two thousand two hundred and forty six children were diagnosed with ADHD by December 31, 2014.

ADHD are not related to the recorded indications but are related to unmeasured factors.

Maternal preconceptional use was not associated with ADHD. This is in line with a recent study in which researchers found no effect of maternal postnatal acetaminophen use on maternal reports of behavior problems.<sup>7</sup> Furthermore, we found that maternal preconceptional use was as associated with use during the first trimester as use across 2 trimesters. This supports the employment of maternal preconceptional use as a negative (or specificity) control and is consistent with a causal link.

The mechanics of the ADHD effect of paternal acetaminophen use before pregnancy are unclear. It may be due to male germ-line epigenetic effects as described in endocrine disruption effects of acetaminophen on the human testis.<sup>15,16</sup>

At least 3 plausible hypotheses are proposed to explain the association between maternal acetaminophen use and ADHD. First, neonatal exposure to acetaminophen changes the levels of brain-derived neurotropic factor in mice and results in altered behavior, lowered fear responses, and reduced learning abilities in adulthood.<sup>33</sup> Brain-derived neurotropic factor promotes neuronal survival and regulates cell migration, axonal and dendritic outgrowth, and formation of synapses.<sup>33–35</sup> Second, acetaminophen could interfere with maternal hormones (such as thyroid hormones and sex hormones) that are related to fetal brain development.<sup>5,15,36–39</sup> Third, acetaminophen could interrupt brain development by induction of oxidative stress, leading to neuronal death.<sup>4,40–42</sup> All of these 3 putative mechanisms can be further tested in experimental animal studies.

**TABLE 3** HRs for Offspring ADHD by Number of Days of Paternal Acetaminophen Use 6 Months Before Pregnancy

No. of Fathers Reporting Each Category		HR <sup>a</sup>	95% CI
No use	64 348	1.00	Reference
1–7 d	8887	1.10	(0.92–1.30)
8–28 d	1079	1.81	(1.26–2.60)
29 or more d	657	2.06	(1.36–3.13)

<sup>a</sup> Adjusted for year of birth, paternal age, and parity.

Our finding that acetaminophen use for <8 days is negatively associated with offspring ADHD indicates that the antipyretic effect could be beneficial with regard to fetal development.<sup>11,12</sup>

We address 3 limitations that could have biased the results. First, although we were able to stratify on each indication of use, long-term use within each indication is likely to represent a more severe form of the disorder. We were not able to adjust for the severity of each condition indicative of acetaminophen use. Second, the ADHD diagnosis was not validated in a research clinic but was based on a diagnosis registered by a specialist in the Norwegian health care system. Finally, young parents and parents who were smokers are underrepresented in MoBa,<sup>43</sup> which

may limit generalization of results to all children. It has, however, previously been shown that although estimates of frequencies and means were biased because of selective participation, selected exposure-outcome associations did not differ between MoBa participants and the general Norwegian population.<sup>43–45</sup>

## CONCLUSIONS

Long-term maternal use of acetaminophen during pregnancy is associated with ADHD in offspring. This holds true even after adjusting for potential confounders, including parental symptoms of ADHD and indications of acetaminophen use. Although maternal preconceptional use was substantially correlated with use during pregnancy, only use

during pregnancy was associated with ADHD. However, given that paternal use of acetaminophen is also associated with ADHD, the causal role of acetaminophen in the etiology of ADHD can be questioned. We do not provide definitive evidence for or against a causal relation between maternal use of acetaminophen and ADHD.

## ACKNOWLEDGMENTS

We thank Ragna Bugge Askeland for assisting in the registry linkage and Ragnhild Eskeland for interpretation of the paternal effects. We are grateful to all the participating families in Norway who take part in this ongoing cohort study.

## ABBREVIATIONS

ADHD: attention-deficit/hyperactivity disorder  
CI: confidence interval  
HR: hazard ratio  
MoBa: Norwegian Mother and Child Cohort Study  
NPR: Norwegian Patient Registry

Accepted for publication Aug 22, 2017

Address correspondence to Eivind Ystrom, PhD, Norwegian Institute of Public Health, PO box 4404 Nydalen, N-0403 Oslo, Norway. E-mail: eivind.ystrom@fhi.no  
PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2017 by the American Academy of Pediatrics

**FINANCIAL DISCLOSURE:** The authors have indicated they have no financial relationships relevant to this article to disclose.

**FUNDING:** Supported by the European Research Council Starting Grant “DrugInPregnancy” (grant 678033) and the Health Sciences and Biology Programme at the Norwegian Research Council (grant 231105). The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research, the National Institute of Environmental Health Sciences (contract N01-ES-75558), and the National Institute of Neurological Disorders and Stroke (grant 1 U01 NS 047537-01 and grant 2 U01 NS 047537-06A1). Funded by the National Institutes of Health (NIH).

**POTENTIAL CONFLICT OF INTEREST:** The authors have indicated they have no potential conflicts of interest to disclose.

**COMPANION PAPER:** A companion to this article can be found online at [www.pediatrics.org/cgi/doi/10.1542/peds.2017-2703](http://www.pediatrics.org/cgi/doi/10.1542/peds.2017-2703).

## REFERENCES

1. Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. *BMJ Open*. 2014;4(2):e004365
2. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol*. 2005;193(3, pt 1):771–777
3. Levy G, Garrettson LK, Soda DM. Letter: evidence of placental transfer of acetaminophen. *Pediatrics*. 1975;55(6):895
4. Brandlistuen RE, Ystrom E, Nulman I, Koren G, Nordeng H. Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. *Int J Epidemiol*. 2013;42(6):1702–1713
5. Liew Z, Ritz B, Rebordosa C, Lee PC, Olsen J. Acetaminophen use during

- pregnancy, behavioral problems, and hyperkinetic disorders. *JAMA Pediatr.* 2014;168(4):313–320
6. Thompson JM, Waldie KE, Wall CR, Murphy R, Mitchell EA; ABC Study Group. Associations between acetaminophen use during pregnancy and ADHD symptoms measured at ages 7 and 11 years. *PLoS One.* 2014;9(9):e108210
  7. Stergiakouli E, Thapar A, Davey Smith G. Association of acetaminophen use during pregnancy with behavioral problems in childhood: evidence against confounding. *JAMA Pediatr.* 2016;170(10):964–970
  8. Cooper M, Langley K, Thapar A. Antenatal acetaminophen use and attention-deficit/hyperactivity disorder: an interesting observed association but too early to infer causality. *JAMA Pediatr.* 2014;168(4):306–307
  9. Xu G, Jing J, Bowers K, Liu B, Bao W. Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis. *J Autism Dev Disord.* 2014;44(4):766–775
  10. Chen SW, Zhong XS, Jiang LN, et al. Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis. *Behav Brain Res.* 2016;296:61–69
  11. Werenberg Dreier J, Nybo Andersen AM, Hvolby A, Garne E, Kragh Andersen P, Berg-Beckhoff G. Fever and infections in pregnancy and risk of attention deficit/hyperactivity disorder in the offspring. *J Child Psychol Psychiatry.* 2016;57(4):540–548
  12. Dreier JW, Andersen AMN, Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. *Pediatrics.* 2014;133(3). Available at: [www.pediatrics.org/cgi/content/full/133/3/e674](http://www.pediatrics.org/cgi/content/full/133/3/e674)
  13. Ystrom E, Vollrath ME, Nordeng H. Effects of personality on use of medications, alcohol, and cigarettes during pregnancy. *Eur J Clin Pharmacol.* 2012;68(5):845–851
  14. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. *Epidemiology.* 2010;21(3):383–388
  15. Albert O, Desdoits-Lethimonier C, Lesné L, et al. Paracetamol, aspirin and indomethacin display endocrine disrupting properties in the adult human testis in vitro. *Hum Reprod.* 2013;28(7):1890–1898
  16. Mazaud-Guittot S, Nicolas Nicolaz C, Desdoits-Lethimonier C, et al. Paracetamol, aspirin, and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with testicular descent. *J Clin Endocrinol Metab.* 2013;98(11):E1757–E1767
  17. Keyes KM, Smith GD, Susser E. Commentary: smoking in pregnancy and offspring health: early insights into family-based and ‘negative control’ studies? *Int J Epidemiol.* 2014;43(5):1381–1388
  18. Magnus P, Birke C, Vejrup K, et al. Cohort profile update: the Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol.* 2016;45(2):382–388
  19. Norwegian Directorate of Health. Norwegian Patient Registry. 2016. Available at: <https://helsedirektoratet.no/english/norwegian-patient-registry>. Accessed July 1, 2016
  20. World Health Organization. *International Statistical Classification of Diseases and Related Health Problems (ICD-10): 10th Rev.* Vol 2. Geneva, Switzerland: World Health Organization; 2004
  21. Sonuga-Barke EJS, Taylor E. ADHD and hyperkinetic disorder. In: Thapar A, Pine DS, Leckman JF, Scott S, Snowling MJ, Taylor E, eds. *Rutter’s Child and Adolescent Psychiatry.* 6th ed. Chichester, UK: John Wiley & Sons, Ltd; 2015:738–756
  22. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. *Psychol Med.* 1987;17(1):121–145
  23. World Health Organization. The Anatomical Therapeutic Chemical Classification System with defined daily doses (ATC/DDD). 2015. Available at: [www.who.int/classifications/atcddd/en/](http://www.who.int/classifications/atcddd/en/). Accessed Nov 16, 2015
  24. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. *Psychol Med.* 2005;35(2):245–256
  25. Tambs K, Moum T. How well can a few questionnaire items indicate anxiety and depression? *Acta Psychiatr Scand.* 1993;87(5):364–367
  26. Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental health status of the Norwegian population: a comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). *Nord J Psychiatry.* 2003;57(2):113–118
  27. Irgens LM. The medical birth registry of Norway. Epidemiological research and surveillance throughout 30 years. *Acta Obstet Gynecol Scand.* 2000;79(6):435–439
  28. Rubin Donald B. *Multiple Imputation for Nonresponse in Surveys.* Vol 81. Hoboken, NJ: John Wiley & Sons; 2004
  29. StataCorp. *Stata Statistical Software [computer program].* Version 14. College Station, TX: StataCorp LP; 2015
  30. Larsson H, Chang Z, D’Onofrio BM, Lichtenstein P. The heritability of clinically diagnosed attention deficit hyperactivity disorder across the lifespan. *Psychol Med.* 2014;44(10):2223–2229
  31. Silberg JL, Maes H, Eaves LJ. Genetic and environmental influences on the transmission of parental depression to children’s depression and conduct disturbance: an extended children of twins study. *J Child Psychol Psychiatry.* 2010;51(6):734–744
  32. Singh AL, D’Onofrio BM, Slutske WS, et al. Parental depression and offspring psychopathology: a children of twins study. *Psychol Med.* 2011;41(7):1385–1395
  33. Viberg H, Eriksson P, Gordh T, Fredriksson A. Paracetamol (acetaminophen) administration during neonatal brain development affects cognitive function and alters its analgesic and anxiolytic response in adult male mice. *Toxicol Sci.* 2014;138(1):139–147
  34. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development



- and function. *Annu Rev Neurosci*. 2001;24:677–736
35. Cui Q. Actions of neurotrophic factors and their signaling pathways in neuronal survival and axonal regeneration. *Mol Neurobiol*. 2006;33(2):155–179
  36. Colborn T. Neurodevelopment and endocrine disruption. *Environ Health Perspect*. 2004;112(9):944–949
  37. Howdeshell KL. A model of the development of the brain as a construct of the thyroid system. *Environ Health Perspect*. 2002;110(suppl 3):337–348
  38. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. *Am J Psychiatry*. 1996;153(8):974–984
  39. Ghassabian A, Bongers-Schokking JJ, Henrichs J, et al. Maternal thyroid function during pregnancy and behavioral problems in the offspring: the generation R study. *Pediatr Res*. 2011;69(5, pt 1):454–459
  40. Dringen R. Metabolism and functions of glutathione in brain. *Prog Neurobiol*. 2000;62(6):649–671
  41. Ghanizadeh A. Acetaminophen may mediate oxidative stress and neurotoxicity in autism. *Med Hypotheses*. 2012;78(2):351
  42. Posadas I, Santos P, Blanco A, Muñoz-Fernández M, Ceña V. Acetaminophen induces apoptosis in rat cortical neurons. *PLoS One*. 2010;5(12):e15360
  43. Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. *Paediatr Perinat Epidemiol*. 2009;23(6):597–608
  44. Gustavson K, Borren I. Bias in the study of prediction of change: a Monte Carlo simulation study of the effects of selective attrition and inappropriate modeling of regression toward the mean. *BMC Med Res Methodol*. 2014;14:133
  45. Gustavson K, von Soest T, Karevold E, Røysamb E. Attrition and generalizability in longitudinal studies: findings from a 15-year population-based study and a Monte Carlo simulation study. *BMC Public Health*. 2012;12:918

## Prenatal Exposure to Acetaminophen and Risk of ADHD

Eivind Ystrom, Kristin Gustavson, Ragnhild Eek Brandlistuen, Gun Peggy Knudsen, Per Magnus, Ezra Susser, George Davey Smith, Camilla Stoltenberg, Pål Surén, Siri E. Håberg, Mady Hornig, W. Ian Lipkin, Hedvig Nordeng and Ted

Reichborn-Kjennerud

*Pediatrics* 2017;140;

DOI: 10.1542/peds.2016-3840 originally published online October 30, 2017;

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://pediatrics.aappublications.org/content/140/5/e20163840">http://pediatrics.aappublications.org/content/140/5/e20163840</a>
<b>Supplementary Material</b>	Supplementary material can be found at: <a href="http://pediatrics.aappublications.org/content/suppl/2017/10/16/peds.2016-3840.DCSupplemental">http://pediatrics.aappublications.org/content/suppl/2017/10/16/peds.2016-3840.DCSupplemental</a>
<b>References</b>	This article cites 39 articles, 3 of which you can access for free at: <a href="http://pediatrics.aappublications.org/content/140/5/e20163840.full#ref-list-1">http://pediatrics.aappublications.org/content/140/5/e20163840.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Developmental/Behavioral Pediatrics</b> <a href="http://classic.pediatrics.aappublications.org/cgi/collection/development:behavioral_issues_sub">http://classic.pediatrics.aappublications.org/cgi/collection/development:behavioral_issues_sub</a> <b>Attention-Deficit/Hyperactivity Disorder (ADHD)</b> <a href="http://classic.pediatrics.aappublications.org/cgi/collection/attention-deficit:hyperactivity_disorder_adhd_sub">http://classic.pediatrics.aappublications.org/cgi/collection/attention-deficit:hyperactivity_disorder_adhd_sub</a> <b>Anesthesiology/Pain Medicine</b> <a href="http://classic.pediatrics.aappublications.org/cgi/collection/anesthesiology:pain_medicine_sub">http://classic.pediatrics.aappublications.org/cgi/collection/anesthesiology:pain_medicine_sub</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="https://shop.aap.org/licensing-permissions/">https://shop.aap.org/licensing-permissions/</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://classic.pediatrics.aappublications.org/content/reprints">http://classic.pediatrics.aappublications.org/content/reprints</a>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN:

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Prenatal Exposure to Acetaminophen and Risk of ADHD**

Eivind Ystrom, Kristin Gustavson, Ragnhild Eek Brandlistuen, Gun Peggy Knudsen, Per Magnus, Ezra Susser, George Davey Smith, Camilla Stoltenberg, Pål Surén, Siri E. Håberg, Mady Hornig, W. Ian Lipkin, Hedvig Nordeng and Ted

Reichborn-Kjennerud

*Pediatrics* 2017;140;

DOI: 10.1542/peds.2016-3840 originally published online October 30, 2017;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/140/5/e20163840>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2017 by the American Academy of Pediatrics. All rights reserved. Print ISSN:

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

